Thomas Alexander, MD, MPH
Assistant Professor
Developmental Therapeutics and Pharmacology
Program Mission
We are active members of the following consortiums offering clinical trials to patients with high-risk, relapsed and refractory malignancies: The mission of the Developmental Therapeutics and Pharmacology program is two-fold.
First, we seek to provide novel, safe, effective therapeutic options to children with high-risk, relapsed, and refractory malignancies. We are carrying out clinical, genomic, and biological research that will enhance care for future generations of children. We are utilizing a combination of UNC investigator-initiated, cooperative group, and pharmaceutical led trials to offer a range of options when precision medicine approaches are indicated, or when standard therapies have failed.
Second, we are utilizing the strengths of the UNC School of Pharmacy and the Lineberger Cancer Center to investigate dosing and toxicity of traditional agents, pharmacology of new molecules, and novel drug delivery mechanisms.
 |
 |
 |
|
|---|
Program Leaders
Patrick Thompson, MD
Professor
Click here to email Drs. Alexander and Thompson to discuss trial eligibility or call 919-966-1178
Developmental Clinical Trials – Currently Open
Developmental Clinical Trials – In Process of Opening
| Diagnosis | Sponsor | Study Title |
|---|---|---|
| Acute Lymphoblastic Leukemia
Relapsed or Refractory |
UNC | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia |
| Neuroblastoma
Relapsed or Refractory |
NANT | NANT11-01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma |
| Neuroblastoma
Relapsed or Refractory |
NANT | NANT15-02: Phase I study of Lorlatinib, an oral small molecule inhibitor of ALK/ROS1, for patients with ALK-driven Relapsed or Refractory Neuroblastoma |
Recent Publications
For additional publications from Drs. Thompson or Alexander, please click here.
- Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. Alexander, T.B., Bhakta, N., Kolb, E.A. & Rubnitz, J.E. (2017). Pediatric Blood & Cancer.
- The genetic basis and cell of origin of mixed phenotype acute leukaemia. Alexander, T.B, et al. (2018). Nature.
- Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU. Lebovic, R., Pearce, N., Lacey, L., Xenakis, J., Faircloth, C.B., & Thompson, P. (2017). Pediatric Blood & Cancer.
- Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia. Smitherman, A.B., Faircloth, C.B., Deal, A., Troy, M., & Gold, S.H. (2017). Pediatric Blood & Cancer.
- Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. Alexander T.B., Lacayo N.J., Choi J.K., Ribeiro R.C., Pui C.H., Rubnitz J.E.. (2016) J Clin Oncol.